Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial

Table 3 Prognostic relevance of T_last

Parameters	Evaluable patient number	Mean T_last (SD)	P value
Best response	53
VGPR or better	47	421.0 days (389.78)	0.032
PR or worse	6	141.8 days (193.07)
Time to best response	51
< 3.3 months	25	261.6 days (389.89)	0.001
≥ 3.3 months	26	535.3 days (333.81)
Long-term outcome	53
Durable remission	9	541.1 days (593.63)	0.372
Progression or death	44	358.3 days (324.25)

Note P values were calculated by Wilcoxon rank-sum test. PR, Partial response; SD, Standard deviation; T_last, Transgene persistence; VGPR, Very good partial response

ISSN: 1756-8722